Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3 Placebo-Controlled, Double-Blind Randomized Withdrawal Study to Evaluate the Efficacy and Safety of BIIB074 in Subjects With Trigeminal Neuralgia

Next Previous
X
Search
Trial Profile

A Phase 3 Placebo-Controlled, Double-Blind Randomized Withdrawal Study to Evaluate the Efficacy and Safety of BIIB074 in Subjects With Trigeminal Neuralgia

Status: Withdrawn prior to enrolment
Phase of Trial: Phase III

Latest Information Update: 31 Jul 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Vixotrigine (Primary)
  • Indications Trigeminal neuralgia
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms SURGE-2
  • Sponsors Biogen

    • Most Recent Events

    • 31 Jul 2023 This trial has been completed in Czechia, according to European Clinical Trials Database record.
    • 22 May 2023 This trial has been discontinued in Hungary and Spain (End Date: 15 Feb 2023), according to European Clinical Trials Database record.
    • 04 May 2023 Status changed from not yet recruiting to withdrawn prior to enrolment.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top